MX347197B - Epitopes de celulas t reguladoras, composiciones y usos para los mismos. - Google Patents

Epitopes de celulas t reguladoras, composiciones y usos para los mismos.

Info

Publication number
MX347197B
MX347197B MX2015014429A MX2015014429A MX347197B MX 347197 B MX347197 B MX 347197B MX 2015014429 A MX2015014429 A MX 2015014429A MX 2015014429 A MX2015014429 A MX 2015014429A MX 347197 B MX347197 B MX 347197B
Authority
MX
Mexico
Prior art keywords
regulatory
compositions
cell epitopes
epitopes
methods
Prior art date
Application number
MX2015014429A
Other languages
English (en)
Spanish (es)
Inventor
Groot Anne De
William Martin
Dan Rivera
Original Assignee
Epivax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39674696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX347197(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Epivax Inc filed Critical Epivax Inc
Publication of MX347197B publication Critical patent/MX347197B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
MX2015014429A 2007-01-30 2008-01-29 Epitopes de celulas t reguladoras, composiciones y usos para los mismos. MX347197B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89834707P 2007-01-30 2007-01-30
PCT/US2008/001148 WO2008094538A2 (en) 2007-01-30 2008-01-29 Regulatory t cell epitopes, compositions and uses thereof

Publications (1)

Publication Number Publication Date
MX347197B true MX347197B (es) 2017-04-18

Family

ID=39674696

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2009008230A MX2009008230A (es) 2007-01-30 2008-01-29 Epitopes de celulas t reguladoras, composiciones y usos para los mismos.
MX2015014429A MX347197B (es) 2007-01-30 2008-01-29 Epitopes de celulas t reguladoras, composiciones y usos para los mismos.
MX2018015933A MX2018015933A (es) 2007-01-30 2009-07-30 Epitopes de celulas t reguladoras, composiciones y usos para los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009008230A MX2009008230A (es) 2007-01-30 2008-01-29 Epitopes de celulas t reguladoras, composiciones y usos para los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018015933A MX2018015933A (es) 2007-01-30 2009-07-30 Epitopes de celulas t reguladoras, composiciones y usos para los mismos.

Country Status (11)

Country Link
US (18) US7884184B2 (OSRAM)
EP (13) EP2450371B1 (OSRAM)
JP (10) JP4866467B2 (OSRAM)
KR (3) KR20100014871A (OSRAM)
CN (4) CN103755789B (OSRAM)
AT (1) ATE525392T1 (OSRAM)
AU (1) AU2008211227B2 (OSRAM)
CA (6) CA2963138C (OSRAM)
IL (3) IL200129A (OSRAM)
MX (3) MX2009008230A (OSRAM)
WO (1) WO2008094538A2 (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4866467B2 (ja) 2007-01-30 2012-02-01 エピバックス インコーポレーテッド 調節性ｔ細胞エピトープ、組成物およびその使用
DE102007030904A1 (de) * 2007-07-03 2009-02-05 Pharis Biotec Gmbh Humanes zirkulierendes antivirales Albumin-Fragment (ALB-408) und seine Verwendung
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
AU2012228100B2 (en) 2011-03-17 2016-09-08 The University Of Birmingham Re-directed immunotherapy
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
ES2618402T3 (es) * 2011-12-13 2017-06-21 Centre National De La Recherche Scientifique Péptidos modificados y su uso para tratar enfermedades autoinmunitarias
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
CA2932798C (en) * 2013-12-06 2022-09-20 The Broad Institute, Inc. Formulations for neoplasia vaccines
PT3981437T (pt) 2014-04-23 2025-01-15 Modernatx Inc Vacinas de ácidos nucleicos
WO2016054114A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
US10213482B2 (en) 2014-12-12 2019-02-26 Immupharma France Sa Methods of treating chronic inflammatory diseases
EP3253419A1 (en) 2015-02-02 2017-12-13 The University of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
JP2018517405A (ja) * 2015-05-04 2018-07-05 エピバックス インコーポレーテッド インフルエンザａ／上海／２／２０１３ ｈ７配列の改変ｈ７赤血球凝集素糖タンパク質
WO2016179099A1 (en) 2015-05-04 2016-11-10 Epivax, Inc. Modified h7 hemagluttinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence
JP7073258B2 (ja) 2015-11-19 2022-05-23 レビトープ リミテッド 望ましくない細胞の再指向性死滅に対する二成分系のための機能的抗体断片相互補完
PL238939B1 (pl) * 2016-11-02 2021-10-18 Instytut Immunologii I Terapii Doświadczalnej Polskiej Akademii Nauk Im Ludwika Hirszfelda We Wrocławiu Peptyd immunosupresyjny i jego zastosowania
AU2018346681B2 (en) 2017-10-05 2024-02-22 Epivax, Inc. Regulatory T cell epitopes
EP3622962A1 (en) * 2018-09-14 2020-03-18 advanceCOR GmbH Short cyclic peptides for the treatment of graves' disease
EP4198513A1 (en) * 2019-05-03 2023-06-21 Epivax Therapeutics, Inc. Neoantigens in cancer
CA3170819A1 (en) 2020-03-27 2021-09-30 Biotest Ag Protein comprising at least one regulatory t cell activating epitope
KR20220160640A (ko) 2020-03-27 2022-12-06 에피백스, 인크. 조절 t-세포 에피토프
CN111856020B (zh) * 2020-06-19 2022-09-27 南方医科大学南方医院 乙型肝炎病毒（hbv）特异性t细胞检测方法及其应用
CA3188962A1 (en) * 2020-08-13 2022-02-17 Anne De Groot Regulatory t cell epitopes
CA3193819A1 (en) * 2020-09-25 2022-03-31 Anne De Groot Retro-inverso regulatory t cell epitopes
EP4370145A1 (en) * 2021-07-16 2024-05-22 DBV Technologies Immunotherapeutic method for increasing cashew tolerance in a subject
AU2024275787A1 (en) 2023-05-19 2025-11-27 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
FR2556219B1 (fr) 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
GB8725529D0 (en) † 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
FR2686899B1 (fr) † 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5817308A (en) * 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6254868B1 (en) 1996-03-20 2001-07-03 Immunomedics, Inc. Glycosylated humanized B-cell specific antibodies
WO1998034957A1 (en) * 1997-02-11 1998-08-13 Immunomedics, Inc. STIMULATION OF AN IMMUNE RESPONSE WITH ANTIBODIES LABELED WITH THE α-GALACTOSYL EPITOPE
JP2002505574A (ja) * 1997-04-30 2002-02-19 エンゾン，インコーポレイテッド ポリアルキレンオキシド修飾された単鎖ポリペプチド
US6953675B2 (en) 1997-11-06 2005-10-11 Immunomedics, Inc. Landscaped antibodies and antibody fragments for clinical use
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6445840B1 (en) 1999-05-28 2002-09-03 Omm, Inc. Micromachined optical switching devices
US6537540B1 (en) 1999-05-28 2003-03-25 Targeted Genetics Corporation Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
AU2001266557A1 (en) † 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
JP2004502946A (ja) † 2000-07-10 2004-01-29 ゼンコー 改変された免疫原性を有するタンパク質ライブラリーを設計するためのタンパク質設計オートメーション
JP2004529633A (ja) * 2001-03-15 2004-09-30 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 低減された免疫原性を有する修飾されたヒトインターフェロンベータ
WO2002079415A2 (en) † 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
ATE469176T1 (de) * 2001-11-12 2010-06-15 Merck Patent Gmbh Modifizierter anti-tnf antikörper
ES2316632T3 (es) † 2001-12-05 2009-04-16 Circassia Limited Metodos y sistemas inmunoterapeuticos.
WO2005077042A2 (en) † 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002364587A1 (en) † 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
JP5424521B2 (ja) † 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
NZ534310A (en) † 2002-02-07 2008-03-28 Novozymes Delta Ltd Albumin-fused anti-angiogenesis peptides
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP1532262B1 (en) 2002-05-24 2013-07-10 Medtronic, Inc. Peptide amidation process
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
CN1511958A (zh) * 2002-12-31 2004-07-14 王小宁 一种筛选人组织相容性抗原(hla)的t细胞表面抗原肽的体系,及其在制备mhc-抗原肽多聚体中的应用
CA2513213C (en) † 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2537055A1 (en) * 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
EP1701979A2 (en) * 2003-12-03 2006-09-20 Xencor, Inc. Optimized antibodies that target the epidermal growth factor receptor
PL2857418T3 (pl) 2004-02-06 2017-10-31 Univ Massachusetts Przeciwciała przeciw toksynom Clostridium difficile i ich zastosowania
BRPI0508670B1 (pt) * 2004-03-19 2023-01-24 Merck Patent Gmbh Proteínas buganina modificadas, citotoxinas, usos das referidas citotoxinas para o tratamento de câncer, composição farmacêutica, processo de preparação de produto farmacêutico, ácidos nucléicos e peptídeos de epítopo de célula t
KR101245983B1 (ko) * 2004-03-31 2013-06-28 제넨테크, 인크. 인간화 항-ｔｇｆ-베타 항체
UA92154C2 (ru) 2004-08-03 2010-10-11 Транстек Фарма, Инк. Rage-слитые белки и способы их применения
AP2007003869A0 (en) 2004-08-03 2007-02-28 Transtech Pharma Inc Rage fusion proteins and methods of use
CU23504A1 (es) * 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
US7488804B2 (en) † 2005-02-02 2009-02-10 The Regents Of The University Of California Modified fusion molecules for treatment of allergic disease
JP2008528668A (ja) * 2005-02-03 2008-07-31 アンチトープ リミテッド ヒト抗体及びタンパク質
JP5215180B2 (ja) 2005-06-20 2013-06-19 メダレックス インコーポレーティッド Ｃｄ１９抗体およびその使用法
EP1924596A4 (en) † 2005-08-12 2009-07-29 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
CN100349921C (zh) * 2005-11-17 2007-11-21 中国人民解放军第四军医大学 破伤风毒素t细胞表位多肽与人b淋巴细胞刺激因子融合蛋白及其制备
ES2439641T3 (es) * 2005-12-20 2014-01-24 Bristol-Myers Squibb Company Composiciones y procedimientos de producción de una composición
KR101516823B1 (ko) * 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
GB0605735D0 (en) 2006-03-22 2006-05-03 Immunobiology Ltd Composition and method for mediating an immune response
WO2007146038A2 (en) † 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
AT503861B1 (de) † 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
JP4866467B2 (ja) * 2007-01-30 2012-02-01 エピバックス インコーポレーテッド 調節性ｔ細胞エピトープ、組成物およびその使用
US20090042254A1 (en) 2007-06-08 2009-02-12 Dow Global Technologies Inc. Expression of soluble antibody fragment by truncation of ch1 domain

Also Published As

Publication number Publication date
CA3034396C (en) 2022-08-02
JP2024059975A (ja) 2024-05-01
US20180289785A1 (en) 2018-10-11
CA2963138C (en) 2019-05-14
US10213496B2 (en) 2019-02-26
US20190030144A1 (en) 2019-01-31
JP2021107444A (ja) 2021-07-29
US20190183994A1 (en) 2019-06-20
EP2450372B1 (en) 2015-04-22
CN101687912B (zh) 2014-01-22
US10925940B2 (en) 2021-02-23
EP2423220B1 (en) 2015-04-29
EP2450368A1 (en) 2012-05-09
CA3001783C (en) 2020-09-08
JP4866467B2 (ja) 2012-02-01
IL267186A (en) 2019-08-29
AU2008211227B2 (en) 2014-04-17
EP2450366A1 (en) 2012-05-09
US10925942B2 (en) 2021-02-23
CA2915168C (en) 2017-05-23
US10980867B2 (en) 2021-04-20
CA3034396A1 (en) 2008-08-07
US20190030143A1 (en) 2019-01-31
US20180289786A1 (en) 2018-10-11
US20190351036A1 (en) 2019-11-21
MX2018015933A (es) 2021-11-16
EP2896630B1 (en) 2020-12-23
KR20140117662A (ko) 2014-10-07
CN101687912A (zh) 2010-03-31
EP2423222A1 (en) 2012-02-29
US20210236609A1 (en) 2021-08-05
US11045529B2 (en) 2021-06-29
US10925939B2 (en) 2021-02-23
US20090018067A1 (en) 2009-01-15
JP2019089793A (ja) 2019-06-13
JP5643739B2 (ja) 2014-12-17
EP2423222B9 (en) 2016-09-14
US20180289782A1 (en) 2018-10-11
IL200129A0 (en) 2010-04-15
EP2423219B1 (en) 2015-04-29
HK1197250A1 (en) 2015-01-09
JP2022177270A (ja) 2022-11-30
JP2017165733A (ja) 2017-09-21
AU2008211227A1 (en) 2008-08-07
US20190183993A1 (en) 2019-06-20
JP2012087128A (ja) 2012-05-10
US20180289787A1 (en) 2018-10-11
JP2014240404A (ja) 2014-12-25
CA3161849A1 (en) 2008-08-07
ATE525392T1 (de) 2011-10-15
KR20100014871A (ko) 2010-02-11
CN103755789A (zh) 2014-04-30
US11045530B2 (en) 2021-06-29
CA2677073A1 (en) 2008-08-07
US20180289788A1 (en) 2018-10-11
MX2009008230A (es) 2010-03-08
EP2423221A1 (en) 2012-02-29
EP2423220A1 (en) 2012-02-29
IL267186B (en) 2020-01-30
US10751397B2 (en) 2020-08-25
CA2963138A1 (en) 2008-08-07
EP2450367A1 (en) 2012-05-09
EP2450371A1 (en) 2012-05-09
US12016909B2 (en) 2024-06-25
EP2125883B2 (en) 2020-11-18
CN103755789B (zh) 2016-12-07
US20110182921A1 (en) 2011-07-28
CN107011431B (zh) 2020-11-06
US10925941B2 (en) 2021-02-23
JP2021073255A (ja) 2021-05-13
EP2450372A1 (en) 2012-05-09
WO2008094538A3 (en) 2009-02-26
US20210252119A1 (en) 2021-08-19
US20160000892A1 (en) 2016-01-07
JP6472476B2 (ja) 2019-02-20
US11844826B2 (en) 2023-12-19
EP2450370A1 (en) 2012-05-09
CA2677073C (en) 2016-03-15
CA2915168A1 (en) 2008-08-07
CN112279911A (zh) 2021-01-29
US20180289784A1 (en) 2018-10-11
US20220211827A1 (en) 2022-07-07
IL245478B (en) 2019-07-31
EP2423221B1 (en) 2015-04-29
EP2450371B1 (en) 2015-04-29
JP2021107443A (ja) 2021-07-29
JP2010516290A (ja) 2010-05-20
EP2896630A1 (en) 2015-07-22
KR20170037677A (ko) 2017-04-04
EP2423222B1 (en) 2015-04-29
US11045528B2 (en) 2021-06-29
EP2450369A1 (en) 2012-05-09
EP2423219A1 (en) 2012-02-29
US20180289783A1 (en) 2018-10-11
US11045531B2 (en) 2021-06-29
US7884184B2 (en) 2011-02-08
US11045532B2 (en) 2021-06-29
EP2125883B1 (en) 2011-09-21
IL200129A (en) 2016-10-31
WO2008094538A2 (en) 2008-08-07
IL245478A0 (en) 2016-06-30
JP6121369B2 (ja) 2017-04-26
EP2125883B9 (en) 2014-04-23
EP2423222B2 (en) 2020-07-29
CA3001783A1 (en) 2008-08-07
CN107011431A (zh) 2017-08-04
KR101722305B1 (ko) 2017-03-31
EP2125883A2 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
MX2009008230A (es) Epitopes de celulas t reguladoras, composiciones y usos para los mismos.
TN2010000213A1 (en) Wise binding antibodies and epitopes
PH12015501848A1 (en) Binding agents
UA111818C2 (uk) Антитіло проти csf-1r
MY174493A (en) Binding agents
MY156315A (en) Anti-vegf antibodies
IL244803B (en) Human anti-beta antibodies and their use
NZ584838A (en) Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof
NZ621170A (en) Anti-human cd52 immunoglobulins
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
TR200807263T1 (tr) IgG'nin FcRn'ye bağlanmasını bloke eden peptidler
TW200732349A (en) Anti-OX40L antibodies and methods using same
MX377605B (es) Inmunoglobulina híbrida conteniendo un enlace no-peptidílico.
DK1948789T3 (da) Fremgangsmåde til fremstilling af permanente, humane cellelinjer
NZ607615A (en) Antibodies directed against il-17
PL1987357T3 (pl) Polipeptydy rozpoznawane przez przeciwciała anty-Trichinella oraz ich zastosowanie
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
WO2005076972A3 (en) Chimeric vegf peptides
WO2010063833A3 (en) Plant growth promoting protein complex
PH12021553121A1 (en) Novel cthrc1-specific antibody and use thereof
WO2010127180A3 (en) Dc-stamp antibodies
WO2011161545A3 (en) Non-hydrolyzable protein conjugates, methods and compositions related thereto
UA100692C2 (ru) Днк-плазмиды, имеющие повышенную экспрессию и стабильность
UA98100C2 (ru) Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его
AU2012261508A1 (en) Wise binding antibodies and epitopes